Related Experiment Video

Updated: Jun 10, 2026

Use of Interferon-γ Enzyme-linked Immunospot Assay to Characterize Novel T-cell Epitopes of Human Papillomavirus
13:41

Use of Interferon-γ Enzyme-linked Immunospot Assay to Characterize Novel T-cell Epitopes of Human Papillomavirus

Published on: March 8, 2012

Human papillomavirus type 16 E5 oncoprotein as a new target for cervical cancer treatment

Mi-Kyung Kim1, Hee Seung Kim, Su-Hyeong Kim

  • 1Department of Obstetrics and Gynecology, Seoul National University College of Medicine, Seoul, Republic of Korea.

Biochemical Pharmacology
|July 21, 2010
PubMed

Insights

Human papillomavirus (HPV) oncoprotein E5 contributes to cervical cancer by altering cell signaling pathways. Targeting HPV 16 E5 offers a potential strategy for cervical cancer chemoprevention and treatment.

Area of Science:

  • Oncology
  • Virology
  • Molecular Biology

Background:

  • Human papillomavirus (HPV) is the primary cause of cervical cancer.
  • HPV E6 and E7 oncoproteins are known to induce malignant transformation by inhibiting p53 and Rb tumor suppressors.
  • The oncogenic role of HPV E5 oncoprotein in cervical carcinogenesis is less understood.

Purpose of the Study:

  • To review the multifaceted roles of HPV 16 E5 in cervical cancer development.
  • To elucidate the mechanisms by which HPV 16 E5 modulates cellular signaling pathways.
  • To highlight the therapeutic potential of targeting HPV 16 E5.

Main Methods:

  • Literature review of studies investigating HPV 16 E5 function.
  • Analysis of evidence linking HPV 16 E5 to cellular signaling pathways.
  • Discussion of HPV 16 E5's contribution to cell proliferation, angiogenesis, and apoptosis.

Main Results:

  • HPV 16 E5, a hydrophobic membrane protein, associates with cellular organelles.
  • Evidence suggests HPV 16 E5 contributes to cervical carcinogenesis by modulating signaling pathways, including EGFR and inflammatory pathways.
  • HPV 16 E5 augments the transforming potential of E6 and E7.

Conclusions:

  • HPV 16 E5 plays a significant role in cervical carcinogenesis.
  • Understanding HPV 16 E5's oncogenic mechanisms is crucial for developing novel therapeutic strategies.
  • Targeting HPV 16 E5 presents a promising avenue for cervical cancer chemoprevention and treatment.

More Related Videos

RNAscope for In situ Detection of Transcriptionally Active Human Papillomavirus in Head and Neck Squamous Cell Carcinoma10:26

RNAscope for In situ Detection of Transcriptionally Active Human Papillomavirus in Head and Neck Squamous Cell Carcinoma

Published on: March 11, 2014

Related Concept Videos

Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Mechanisms of Retrovirus-induced Cancers01:51

Mechanisms of Retrovirus-induced Cancers

Retroviruses are RNA viruses that have been shown to cause cancers in diverse species, including chickens, mice, cats, and monkeys. The RNA genomes of these viruses are first reverse-transcribed into single and then double-stranded DNA (dsDNA) copies. This dsDNA called proviral DNA then integrates into the host genome. Subsequently, the host cell transcribes the proviral DNA in concert with the chromosomal DNA. This leads to the production of viral RNA and proteins that assemble at the host...
Mechanisms of Retrovirus-induced Cancers01:51

Mechanisms of Retrovirus-induced Cancers

Retroviruses are RNA viruses that have been shown to cause cancers in diverse species, including chickens, mice, cats, and monkeys. The RNA genomes of these viruses are first reverse-transcribed into single and then double-stranded DNA (dsDNA) copies. This dsDNA called proviral DNA then integrates into the host genome. Subsequently, the host cell transcribes the proviral DNA in concert with the chromosomal DNA. This leads to the production of viral RNA and proteins that assemble at the host...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.